← Back to Clinical Trials
Recruiting NCT06982677

NCT06982677 Improving Outcomes in Early Menopause After Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06982677
Status Recruiting
Phase
Sponsor Duke University
Condition Early Menopause
Study Type INTERVENTIONAL
Enrollment 117 participants
Start Date 2026-01-20
Primary Completion 2027-05

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 44 Years
Study Type INTERVENTIONAL
Interventions
Nurse Navigator InterventionEducation Control

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 117 participants in total. It began in 2026-01-20 with a primary completion date of 2027-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to create and test a new program led by nurse navigators to help women who experience early menopause after cancer. The program includes personalized menopause education, decision support, and skills to manage menopause symptoms. The main questions it aims to answer are: 1. Is the program easy to join, engaging, and well-received by participants? 2. Does the program group show greater improvements in knowledge, decision-making, confidence, and menopause symptom management compared to the control group? Participants will complete sessions of either the program being tested or an educational control program with a nurse navigator via video. Participants will also complete questionnaires when they start the study and again about 10 weeks later.

Eligibility Criteria

Inclusion Criteria: * female (biological sex); * 18 to 44 years old; * completed cancer treatment (other than endocrine therapy) \>12 months prior to enrollment; * have not had a period for more than 12 months (amenorrhea); * able to speak and read English. Exclusion Criteria: * diagnosis of metastatic cancer; * visual or hearing impairment that would interfere with participation in study; * cognitive impairment or severe mental illness that would interfere with participation in study.

Contact & Investigator

Central Contact

Smrithi Divakaran, MPH

✉ smrithi.divakaran@duke.edu

📞 919-681-7695

Principal Investigator

Rebecca Shelby, PhD

PRINCIPAL INVESTIGATOR

Duke University

Frequently Asked Questions

Who can join the NCT06982677 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 44 Years, studying Early Menopause. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06982677 currently recruiting?

Yes, NCT06982677 is actively recruiting participants. Contact the research team at smrithi.divakaran@duke.edu for enrollment information.

Where is the NCT06982677 trial being conducted?

This trial is being conducted at Durham, United States.

Who is sponsoring the NCT06982677 clinical trial?

NCT06982677 is sponsored by Duke University. The principal investigator is Rebecca Shelby, PhD at Duke University. The trial plans to enroll 117 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology